Key facts
- Actio Biosciences’s last known valuation is $137.0M (Jun 2025).
- It has raised $121.0M; the latest was Early Stage VC ($66.0M) in Jun 2025.
- Notable investors include Canaan Partners, Deerfield Management, Euclidean Capital, EcoR1 Capital, Droia Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Actio Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Actio Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Actio Biosciences
Developer of a portfolio of drugs designed to cure rare diseases that could also help treat common illnesses. The company's portfolio uses biotechnology that modulates the activity of proteins responsible for rare diseases with the potential to translate these findings into finding cures for common diseases, enabling patients to get treatments for diseases that are hard to cure.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 42
- Website
- actiobiosciences.com/
- Ownership
- Privately Held (backing)
Actio Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Actio Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Actio Biosciences in its N-PORT filings yet. We sweep new filings monthly.